
Evidence analysis
Human medicines European public assessment report (EPAR): Livtencity, maribavir, Date of authorisation: 09/11/2022, Revision: 9, Status: Authorised
Evidence Dossier: Livtencity (maribavir) for Cytomegalovirus Infection in Transplant Patients What is Established Livtencity is an antiviral medication authorized for use in the European Union as of November 2022. Its active ingredient, maribavir, is indicated for the treatment…
Read →
Evidence analysis
Human medicines European public assessment report (EPAR): Herwenda, trastuzumab, Date of authorisation: 15/11/2023, Revision: 4, Status: Authorised
FreedomWitness Evidence Article: Evaluation of Herwenda (trastuzumab biosimilar) by EMA What is established Herwenda is a biosimilar medicine containing trastuzumab, authorised for use in the European Union since November 2023. It is intended to treat HER2-positive cancers, specifically…
Read →
Evidence analysis
Scientific advice for veterinary medicines
Scientific Advice on Veterinary Medicines: An Evidence Overview What is established The European Medicines Agency (EMA) provides scientific advice to companies developing veterinary medicines. This service aims to guide medicine developers on the appropriate tests and studies during…
Read →
Evidence analysis
Understanding vaccines: key scientific terms and platforms
Understanding Vaccines: Key Scientific Terms and Platforms Vaccines remain a cornerstone of public health strategies worldwide. However, understanding them requires familiarity with specific scientific terms and concepts. A report dated November 9, 2026, from a European regulatory agency…
Read →
Evidence analysis
Mandate, objectives, and rules of procedure for working parties under the quality, non-clinical, methodology, clinical and veterinary domains
Mandate and Objectives of EMA Working Parties in Pharmaceutical Domains This dossier reviews information from the European Medicines Agency (EMA) document titled “Mandate, objectives, and rules of procedure for working parties under the quality, non-clinical, methodology, clinical and…
Read →
Evidence analysis
Concerns raised over older heavy drinkers
What is established Recent public health data from the Centers for Disease Control and Prevention (CDC) indicates that alcohol consumption patterns in the United States have shifted notably in the years following the COVID-19 pandemic. While younger adults…
Read →
Evidence analysis
Human medicines European public assessment report (EPAR): Aldurazyme, laronidase, Date of authorisation: 09/06/2003, Revision: 28, Status: Authorised
What is established Aldurazyme is a medicinal enzyme replacement therapy containing the active substance laronidase. It is approved in the European Union for the treatment of mucopolysaccharidosis I (MPS I), a rare inherited metabolic disorder caused by a…
Read →
Evidence analysis
Human medicines European public assessment report (EPAR): Yorvipath, palopegteriparatide, Date of authorisation: 17/11/2023, Revision: 6, Status: Authorised
What is established Yorvipath is a hormone replacement therapy authorized by the European Medicines Agency (EMA) for treating adults with chronic hypoparathyroidism, a rare endocrine disorder characterized by insufficient production of parathyroid hormone (PTH). The active substance in…
Read →
Evidence analysis
Human medicines European public assessment report (EPAR): Rivaroxaban Viatris (previously Rivaroxaban Mylan), rivaroxaban, Date of authorisation: 12/11/2021, Revision: 12, Status: Authorised
Evidence Dossier: Rivaroxaban Viatris – Health & Science What is established Rivaroxaban Viatris is an anticoagulant medication authorized for use in the European Union since November 12, 2021. It contains the active substance rivaroxaban, a direct factor Xa…
Read →
Evidence analysis
Human medicines European public assessment report (EPAR): Vabysmo, faricimab, Date of authorisation: 15/09/2022, Revision: 11, Status: Authorised
Evidence Dossier: Vabysmo (faricimab) – Treatment for Retinal Diseases What is established Vabysmo is a medicine containing the active ingredient faricimab, authorized in the European Union since September 15, 2022, for treatment of certain retinal diseases affecting adults.…
Read →